Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro.

Gene Therapy

Volumn 6, Issue 5, 1999, Pages 845-853

  Diao, J ^a   Smythe, J A ^a   Smyth, C ^a   Rowe, P B ^a   Alexander, I E ^a,b,c  

^a CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c New Children's Hospital   (Australia)

Author keywords

Adenovirus vector; Dendritic cells; Immune response

Indexed keywords

ANTIGEN; BETA GALACTOSIDASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; TUMOR ANTIGEN; VACCINE; VIRUS VECTOR;

ADENOVIRUS; ADENOVIRUS 5; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER MODEL; CELL PROLIFERATION; CELL PROTECTION; CELL STRUCTURE; CULTURE MEDIUM; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IN VITRO STUDY; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; BETA-GALACTOSIDASE; CANCER VACCINES; CELLS, CULTURED; DENDRITIC CELLS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICROSCOPY, CONFOCAL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS); CUCUMBER MOSAIC VIRUS; HUMAN ADENOVIRUS TYPE 5; MURINAE;

EID: 0032980749     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300899     Document Type: Article

References (51)

1. Knuth A, Wolfel T, Meyer zBK. T cell responses to human malignant tumours. Cancer Surv 1992; 13: 39-52.
2. Schneider SC, Sercarz EE. Antigen processing differences among APC. Hum Immunol 1997; 54: 148-158.
3. Castellino F, Zhong G, Germain RN. Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking and the molecular basis of diverse determinant capture. Hum Immunol 1997; 54: 159-169.
4. Maffei A, Papadopoulos K, Harris PE. MHC class I antigen processing pathways. Hum Immunol 1997; 54: 91-103.
5. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996; 17: 131-137.
6. Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995; 7: 682-686.
7. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
9. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-261.
10. + progenitors in human bone marrow. J Immunol 1992; 149: 2681-2688.
11. Santiago-Schwarz F, Belilos E, Diamond B, Carsons SE. TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. J Leuk Biol 1992; 52: 274-281.
12. + leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leuk Biol 1996; 59: 208-218.
13. + dendritic cells. Proc Natl Acad Sci USA 1996; 93: 2588-2592.
14. Mayordomo JI et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15: 94-103.
15. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997; 186: 1183-1187.
16. Mayordomo JI et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995; 1: 1297-1302.
17. Zitvogel L et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97.
18. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70: 706-715.
19. Song W et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186: 1247-1256.
20. Specht JM et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186: 1213-1221.
21. Ashley DM et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or rumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186: 1177-1182.
22. Wan Y et al. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8: 1355-1363.
23. Ribas A et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 1997; 57: 2865-2869.
24. Gong J et al. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Therapy 1997; 4: 1023-1028.
25. Hsu FJ et al. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2: 52-58.
26. Nestle FO et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4: 328-332.
27. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465-472.
28. Arthur JF et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25.
29. Brossart P et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997; 158: 3270-3276.
30. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998; 91: 392-398.
31. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
32. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
33. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
34. Rich DP et al. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum Gene Ther 1993; 4: 461-476.
35. Grunhaus A, Horwitz MS. Adenoviruses as cloning vectors. Semin Virol 1992; 3: 237-252.
36. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity (comment). J Exp Med 1996; 183: 7-11.
37. Juillard V et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995; 25: 3467-3473.
38. Wickham TJ et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol 1997; 71: 7663-7669.
39. Huang S, Endo RI, Nemerow GR. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 1995; 69: 2257-2263.
40. Bergelson JM et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998; 72: 415-419.
41. Rogers BE et al. Use of a novel cross-linking method to modify adenovirus tropism. Gene Therapy 1997; 4: 1387-1392.
42. Hardy S et al. Construction of adenovirus vectors through Crelox recombination. J Virol 1997; 71: 1842-1849.
43. Acsadi G et al. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum Molec Genet 1994; 3: 579-584.
44. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
45. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ (ed). Gene Transfer and Expression Protocols. Humana Press: Clifton, NJ, 1991, pp 109-128.
46. Miller DG, Edwards RH, Miller AD. Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci USA 1994; 91: 78-82.
47. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992; 158: 97-129.
48. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
49. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Meth Enzymol 1993; 217: 581-599.
50. Halbert CL, Alexander IE, Wolgamot GM, Miller AD. Adenoassociated virus vectors transduce primary cells much less efficiently than immortalized cells. J Virol 1995; 69: 1473-1479.
51. Schevzov G et al. Tropomyosin localisation reveals distinct populations of microfilaments in neurites and growth cones. Mol Cell Neurosci 1997; 8: 439-454.